Ionic Wind’s technology generates airflow using high-voltage electric fields, replacing rotating fans with modules that have no moving parts. This enables targeted, high-velocity airflow in ultra-thin form factors, making it ideal for compact electronics such as edge-AI computers, high-performance laptops, industrial sensor modules, and single-board computers—where noise, thermal limits, and space constraints are critical. By removing mechanical components, the modules reduce noise, vibration, and wear, allowing devices to operate cooler, quieter, and more reliably.

The solid-state design also provides new flexibility for device engineers. Modules can be embedded along edges, behind chipsets, or within structural elements, creating airflow paths previously impossible. This capability allows thermal performance to scale without increasing device size.

Founded in 2025, Ionic Wind is currently working on multiple customer projects targeting high-density electronics and edge-AI devices. The new funding will advance product certification, expand intellectual property, and complete final steps toward market readiness.

The cleantech startup has recently won the last stage of Venture Kick.

Ionic Wind Technologies CEO Donato Rubinetti, CTO Liubov Shishaeva, and Executive Director Rico Chandra

Additional Links
Ionic Wind's profile on Venture Kick Ionic Wind Technologies obtains the CHF 150,000 Kick to boost the air-cooling efficiency of electronics and data centers

Every day, delayed or unreliable field drug tests put communities, first responders, and workers at risk. Current solutions often require laboratory analysis, involve long processing times, or lack accuracy in real-world environments. Whether at roadside controls, workplaces, or public events, decision-makers increasingly need rapid, trustworthy tools to assess situations and respond safely.

The medtech startup Altiscreen develops portable testing devices that provide fast and accurate detection of multiple substances using oral fluid, urine, or trace samples. Results are available in around three minutes, enabling immediate decision-making and significantly reducing the need for laboratory follow-up. The technology is suited for a wide range of applications, including healthcare, workplace safety, law enforcement, and event management, where dependable on-the-spot screening is essential.

Combining a fast-growing pipeline with a scalable business model, Altiscreen aims to deploy several thousand drug-screening devices per year worldwide in the coming years, helping improve safety on the road and in the workplace. With drug consumption rising globally, the startup has strong potential and a clear strategic plan for the years ahead.

The CHF 150,000 from Venture Kick will be allocated mainly to sales and marketing activities, including customer visits, product demonstrations, and outbound initiatives. Part of the funding will also support R&D and the expansion of Altiscreen’s production capacity.

Altiscreen was founded in 2024 by Dr. Leonard Dumea, who brings experience in developing practical, field-ready diagnostic technologies. Focused on reliability, portability, and ease of use, the team aims to make rapid drug screening more accessible across multiple sectors.

“Venture Kick was crucial in Altiscreen’s development. We found the right mix of experience, know-how, and guidance to advance our venture,” said CEO and co-founder Leonard Dumea. “We are pleased with the progress made over the past months, which is partly due to Venture Kick’s support. We thank the Venture Kick team and jury members for their trust and look forward to meeting them in our next equity round.”

Altiscreen’s co-founders: CEO Leonard Dumea and CFO Florian Saner

Additional Links
Altiscreen's profile on Venture Kick CHF 40,000 for a device for rapid on-site drug detection

Digital sovereignty is increasingly prioritized across Europe, yet smartphones remain dependent on un-auditable operating systems. Large-scale outages and security breaches have shown how this reliance can disrupt governments, emergency services, and industries.

Recent Venture Kick recipient Soverli introduces an architecture that works alongside existing operating systems, allowing multiple isolated environments to run on a single device. Users retain the full Android experience while gaining access to a sovereign, auditable OS that can be switched to in milliseconds. In a recent demonstration, Signal ran inside this environment with a sharply reduced attack surface, ensuring confidentiality even if the main OS is compromised.

The company’s first application focuses on mission-critical communication, with public-sector pilots underway. If Android fails due to misconfiguration or attack, the isolated environment continues to operate, ensuring essential workflows remain available. Enterprises are also exploring the system for secure bring-your-own-device setups that separate personal and professional use.

As Europe accelerates efforts around digital sovereignty, smartphones remain a major unresolved gap. Soverli’s approach offers institutions a way to introduce their own security posture on commercial devices without custom hardware. With the new funding, the team will expand engineering, broaden device support, and strengthen integrations with mobile device management systems.

CEO Ivan Puddu and CTO Moritz Schneider

Additional Links
Soverli's profile on Venture Kick Soverli has received CHF 150,000 from Venture Kick to drive digital sovereignty by reshaping smartphone security

DigeHealth has raised CHF 1.25 million in seed funding, which will accelerate its work on gastrointestinal (GI) health solutions. The funding will allow the medtech startup to develop its next-generation GI monitoring technology.

Designed to provide continuous, objective insights, this solution aims to transform care for patients with common and complex digestive disorders, including Irritable Bowel Syndrome (IBS), Inflammatory Bowel Diseases (IBD), and bowel obstructions. By delivering more precise and actionable data, DigeHealth’s technology seeks to improve diagnosis, treatment, and patient outcomes in ways previously unattainable.

The medtech startup has participated in Venture Leaders Medtech and received backing by Venture Kick. “Venturelab supported us at two key inflection points—first at the ideation stage through early financing, and later this year through the Venture Leaders Medtech program." highlighted CEO Nour Ghalia Abassi. "Both programs, Venture Kick and Venture Leaders, helped shape the trajectory of DigeHealth. The role Venturelab plays in the entrepreneurial ecosystem is fundamental for Swiss early-stage startups, it is a true proving ground where founders are forged.”

DigeHealth team: Nour Ghalia Abassi, Till Gerken, and Christian Frei

Additional Links
DigeHealth profile on Venture Kick

Swiss startup Corintis, headquartered in Lausanne, has raised an additional USD 25 million in funding led by Applied Digital, bringing its total to around USD 58 million. The company will use the capital to accelerate global expansion, scale manufacturing, and support commercialization with major technology and data-center operators, addressing the growing challenge of cooling next-generation AI hardware.

Corintis develops advanced microfluidic liquid-cooling technology that channels coolant directly through microscopic pathways inside chips. This method can lower chip temperatures up to three times more effectively than traditional cold-plate systems. Microsoft has already validated the technology, highlighting its potential to support increasingly powerful and densely packed AI processors.

With the new funding, Corintis plans to expand its U.S. presence, including a new office in Bellevue, Washington, while ramping up production and accelerating deployments worldwide. By providing scalable, energy-efficient cooling solutions, the company aims to become a key player in powering high-performance, next-generation data centers.

The engineering company has consistently stood out, participating in Venture Leaders Mobile, winning Venture Kick, and ranking among the Top100 Swiss Startups for four consecutive years.

Oncobit, a precision oncology company developing next-generation cancer monitoring solutions, has bolstered its financial base through a new capital increase backed by existing and new investors, including private business angels and strategic partner ID Solutions (IDS). The funding reinforces the company’s capacity to advance clinical validation work, progress with regulatory requirements, and continue its commercialization plans. It also positions Oncobit to further expand its portfolio into additional cancer indications and enter new markets, drawing on its IVDR and ISO 13485 certifications and its network of clinical and industry partners.

Founded in 2018 as a spinoff from the University of Zurich, a Venture Kick funding recipient and a Venture Leaders Medtech participant, Oncobit has built a scalable, data-driven cancer monitoring platform designed to detect cancer-related markers in liquid biopsies with high sensitivity and quantitative precision. With a focus on clinically relevant biomarkers and the use of advanced technology, the company offers cost-efficient and time-efficient tools that allow for close monitoring of a patient’s condition and support informed therapy decisions.

The company’s cloud-based software for data analysis and interpretation, trained on both healthy and patient datasets, provides consistent and robust result reporting. Oncobit’s diagnostic solutions are now used by an expanding group of pharmaceutical companies, clinical laboratories, and hospital institutions.


Oncobit's team

Additional Links
Oncobit's profile on Venture Kick

Complex systems such as smartphones, autonomous vehicles, or drones are now part of everyday life. As these technologies evolve, ensuring their reliability and safety becomes increasingly difficult. Engineers face growing pressure to deliver products faster and at lower cost while navigating rising system complexity, workforce shortages, and stringent compliance requirements. Traditional risk analysis methods struggle to keep pace with these demands, making innovation both costly and slow.

The CERN spin-off Reshape Systems develops an AI-driven software solution that automates and enhances the risk analysis process for complex systems. Acting as a risk analysis co-pilot, the platform uses generative AI to manage the most time-consuming and error-prone tasks, assisting engineers and domain experts in identifying, documenting, and mitigating potential risks. The result is up to 80% lower engineering costs, 10 times faster product development, and improved system reliability across industries such as automotive, aerospace, and consumer electronics.

Reshape targets the large risk analysis market, which includes industrial sectors such as transportation, aerospace, and energy. These industries currently spend over $12 billion annually on risk analysis, and this expenditure is expected to grow significantly in the coming years due to increasing safety challenges associated with emerging technologies such as drones.

The CHF 150,000 from Venture Kick will enable a quick team expansion and to accelerate the development and implementation of Reshape’s product roadmap. 

Dr. Andrea Apollonio and Dr. Thomas Cartier-Michaud co-founded the company after more than ten years of experience in industrial risk analysis and artificial intelligence. Their combined expertise in high-stakes engineering environments and advanced data-driven methods enables the ICT startup to bring a new generation of intelligent tools to the engineering software market.

“Venture Kick has been a key enabler to push our sales pipeline and sharpen our product roadmap,” highlighted CEO Andrea Apollonio.

Reshape Systems co-founders Thomas Cartier-Michaud and Andrea Apollonio

Additional Links
Reshape Systems' profile on Venture Kick Reshape Systems secures CHF 800,000 to expand AI-driven risk analysis for complex industries

Insurance today is scattered across emails, portals, PDFs, credit-card benefits, and embedded products. This fragmentation makes it extremely difficult for brokers to access structured information and deliver timely guidance to their clients.

The ICT startup Humbrela solves this by building a unified intelligence layer that consolidates all policies and warranties, automatically extracts key protections, and transforms complex clauses into simple, operational insights professionals can use.

Because insurance involves risk, money, and emotion, people continue to rely on a human advisor. And at a time when generic AI models like ChatGPT show only 52% accuracy on insurance-specific content, the industry needs tools built specifically for its complexity, not generic chatbots.

The company has already onboarded its first brokers in Switzerland and France and initiated strong discussions with wholesale brokers and MGAs across Europe. With over €100B generated annually from brokerage activity, the opportunity to modernize the industry is significant, and Humbrela aims to become the intelligence layer powering this transformation.

The CHF 150,000 from Venture Kick will be used to improve Humbrela’s AI models for policy understanding and risk-gap detection, expand integrations with insurers, warranty providers, and TPAs, strengthen compliance across EU, Swiss, and UK markets, and support the company’s expansion with brokers, wholesale brokers, and MGAs.

Humbrela is led by a strong founding team combining Semchs Zaidi (CEO), bringing 20 years of sales and customer-experience expertise; Simon Mazas (CTO), with 20 years of insurance software engineering; Mathieu Chabasse (CPO), with 15 years of product and UX leadership; and Sarah El Abshihy (Legal Counsel), contributing deep EU/CH/UK regulatory expertise.

“Venture Kick played an essential role in helping us validate our solution in the field and move fast. They gave us structure, clarity, and focus at each stage. They were the first to support us, and that made a real difference,” highlighted CEO Semchs Zaidi.


Humbrela's team from left to right: Semchs Zaidi (CEO), Simon Mazas (CTO), Léa Lacoste (AI Engineer), Sarah El Abshihy (Legal Counsel), Mathieu Chabasse (CPO), Andrew de Rozairol (Mentor)

Additional Links
Humbrela's profile on Venture Kick

CDDS: Drones to protect life and infrastructure
The rapid spread of small, fast, and affordable drones creates urgent security risks for critical infrastructure and crowded urban spaces. Existing counter-UAS measures are too slow or intrusive to protect people and assets reliably.
CDDS AG, founded by experienced Swiss deep-tech entrepreneurs and robotics experts, develops autonomous, lightweight interceptor drones that detect, track, and kinetically neutralize hostile drones with real-time vision, reinforcement learning, and ultra-low-latency control. The global counter-UAS market is projected to exceed USD 3 billion within a few years, offering strong growth potential.
The company will utilize the Venture Kick funding to enhance CDDS’s visibility and recruit top engineers with expertise in drones, PX4, and/or ROS, thereby accelerating product development and preparing for large-scale field deployments.

QENDRA: Powering the next generation of quantum computers
Quantum computers will revolutionize drug discovery, logistics, and climate modelling by harnessing quantum mechanics. Trapped-ion and neutral-atom quantum computers are among the most advanced, but they lack reliable, scalable control systems.
QENDRA provides the missing link: a dedicated control system that bridges the classical and quantum worlds. Built from technology developed in the trapped ion quantum information group at ETH Zurich, their MVP offers unmatched efficiency and rapid setup times. CEO Dr. Martin Stadler, COO Dr. Ferdinand Felder, and lead developer Chidzahi Mabritto, together with a team of scientists and engineers, are bringing this innovation to market. With growing demand from research groups and startups, QENDRA is poised to serve a fast-expanding global quantum computing market.
The Venture Kick funds will help QENDRA engage new customers, build a solid IP strategy, and advance CE certification of its MVP. qendratech.com

Tuus: Enabling athletes to perform at their best today, and empowering broader health solutions tomorrow
Endurance athletes often rely on energy gels that trigger sugar spikes, stomach distress, and uneven performance. Tuus addresses this by introducing a controlled-release hydrogel that ensures stable energy delivery without compromising health.
Founded by chemists Pietro Nasturzio and Tiziano Caldara, Tuus combines expertise in materials science, nutrition, and drug delivery. Supported by advisors from academia, sports medicine, industry, and design, the team has built a breakthrough edible hydrogel platform for constant release of active compounds. The first application is a next-generation energy gel, now entering clinical trials with athletes, marking a decisive step toward healthier endurance fueling. Beyond sports, the same platform can be applied in nutraceuticals and pharmaceuticals, where controlled release has the potential to transform health and well-being.
Tuus will use the Venture Kick funds to advance customer testing with precise glucose monitoring equipment, prototype for industrial integration with manufacturing partners, cover licensing contract negotiation fees with lawyers, and support investor networking.

Askalon Industries: Passive Acoustic AI for Drone Threat Detection
The rapid rise of low-cost, autonomous, and RF-silent drones has outpaced today’s security tools. Airports, prisons, utilities, and government sites face growing operational and safety risks, while radar and RF systems remain either too expensive or ineffective against modern silent threats. The market urgently needs a scalable, passive, and reliable way to protect wide areas without military-grade budgets or detectable emissions.
Askalon listens to the sky to detect threats that others can’t see, with the mission of building the acoustic AI backbone that secures Europe’s low-altitude airspace. Founded in Lausanne in 2025, Askalon’s team unites expertise in acoustics, embedded AI, and edge hardware. Their proprietary passive acoustic system detects and locates drones in real-time—even in high-noise environments—at a cost 10–50x lower than radar or optical alternatives. This affordability enables the deployment of dense sensor networks and addresses a multi-billion-euro global market across critical infrastructure, defense, and urban security. With a growing proprietary dataset and an MVP launching in Q1 2026, Askalon aims to become a core element of Europe’s low-altitude security architecture.
Venture Kick funding will support the shift from validated prototypes to an industrial MVP, including hardware refinement, expanded field data acquisition, and early pilot deployments with strategic customers. These steps accelerate commercial readiness for 2026 and reinforce Askalon’s lead in passive drone detection.

Baio: Streamlining early-stage drug discovery
Traditional early-stage drug discovery depends on screening chemical libraries, a costly and time-consuming process that explores only a tiny fraction of the astronomically large chemical space. Depending on the therapeutic target, these workflows can take several years and cost millions of dollars.
Baio reshapes early-stage drug discovery by exploring the entire chemical space with generative AI and designs novel drug candidates in a fraction of the time. Baio is an EPFL spin-off founded by PhD students Ilia Igashov and Arne Schneuing, together with Professor Bruno Correia. Over the past years, the team has pioneered the field of generative AI for structure-based drug discovery and developed a set of tools that have been widely adopted by the community. At Baio, they aim to help pharmaceutical and biotechnology companies accelerate their pre-clinical R&D pipelines.
Venture Kick funding will enable Baio to gather experimental evidence to de-risk and further refine its core technology.

Dental Robotics: Enabling preventive dental care anywhere with an ultra-portable dental system.
Dental Robotics addresses the global burden of oral disease, which affects 3.5 billion people and is linked to chronic conditions such as Alzheimer’s, Parkinson’s, cardiovascular disease, and premature birth. Today, preventive dental care is constrained by bulky equipment and clinic-based workflows, limiting access for patients and restricting flexibility for hygienists.
Founded by Dr. Arthur Sebesteny, a dentist with five years of clinical experience, and Kinga Ory, a former HR manager with eight years of expertise in PR, marketing, and project management, the startup develops a lightweight, portable 3-in-1 dental hygiene system paired with a digital platform that connects patients, hygienists, and dentists - creating an “on-demand dental hygiene” model. They target a USD 25B global market, with the U.S. as the largest opportunity, where 42 states allow hygienists to work independently. Market demand has been validated through a signed LOI for 100 units from JetDental, a major U.S. mobile dental service provider. 
The Venture Kick funds will support product development and market validation.
dentalrobotics.ch

Ninsun Biotech: Predict tumor aggression regardless of stage, predict non-response to neoadjuvant treatments in lung cancer
In early-stage lung cancer, many patients classified as Stage I actually harbor highly aggressive tumors that relapse soon after surgery. Clinicians currently lack a reliable tool to identify these high-risk patients or to know who will truly respond to neoadjuvant immunotherapy. Ineffective treatment delays surgery, increases complications, and wastes EUR 25–50k per patient.
Ninsun Biotech was founded by Dr. Vincent Carré (PhD), Dr. Sylvain Gnaho, and Dr. Chandouri (PhD), supported by an international network of experts in thoracic oncology, pathology, and health economics. The company has developed Ninstem Lung, the first CE-marked and clinically validated prognostic test capable of detecting tumor aggressiveness at any operable stage. Ninsun is now validating its predictive use to select responders to neoadjuvant immunotherapy and targeted therapies — addressing a market of 260,000 operable NSCLC patients in Europe each year.
Venture Kick funding will be used to expand the clinical cohort in Switzerland and France and to advance AI-assisted slide interpretation, boosting predictive performance and accelerating adoption toward commercialization.

Roofless labs: Bridging the gap between creators and 3D photography
Stereoscopic images, also known as 3D gifs or  “wigglegrams,” are on the rise, but creating them currently requires buying expensive and rare vintage cameras, film development, and complex manual editing skills in Photoshop. The process is slow, costly, and unscalable for the digital age.
Roofless Labs, incorporated in 2025 by CEO Maïkor Juvet and CTO Jean-Baptiste Michel, introduces K4MERA. This product is a digital "point-and-shoot" that combines four synchronized lenses and a custom AI pipeline to instantly generate 3D GIFs, removing all post-production complexity. They are primarily targeting the booming creator economy, starting with the confirmed  20k+ wigglegram enthusiasts and millions of creators seeking differentiation in a market anticipated to be worth nearly half a trillion dollars. This segment fits within the growing 3D camera market, which is projected to expand from USD 1.59 billion to USD 3.49 billion by 2030.
Roofless Labs will use the Venture funds to finalize its prototype architecture with CSEM support. This capital will allow the company to produce high-quality demo content and conduct essential user testing.